RxDoctor Payments Data

Monica Lovins

Adult Health · Baltimore, MDNPI 1861732331

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,945 of the $17,822 with a category attached, or 78.2%. 37 manufacturers reported payments, led by Gilead at 31.2% of the total. 2025 is the largest year on record at $7,098, 3.1 times the $2,265 reported in 2021. Among adult health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,822in general payments, 2019–2025

Across 692 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$6K
  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Bristol Myers Squibb$1K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$643
  • plus $6K from 31 others

What the payments were for

  • Consulting fees$2,64015%
  • Travel & lodging$1,0416%
  • Food & beverage$13,94578%
  • Education$1951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,822 in reported general payments places this provider in the 95th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Medicare billing

Part B allowed, 2024
$25,857
Medicare patients
127
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin19$88,167
CreonLipase/Protease/Amylase18$45,913
Mesalamine ErMesalamine68$21,595
LinzessLinaclotide16$19,200
Budesonide EcBudesonide20$5,258
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C34$4,729
Budesonide DrBudesonide24$3,927
Famotidine133$2,330
Pantoprazole Sodium69$1,040
Prednisone34$218
Dicyclomine Hcl16$194
Terazosin Hcl23$178
Ondansetron Hcl21$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$1,121$92,89653 claims
AbbVieCreon, Linzess$2,523$65,11334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 adult health providers in Maryland.

Other adult health in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →